AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, ...

Jan. 9, 2025 — A new study demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient ...

引言胰腺癌（Pancreatic cancer）是全球癌症相关死亡的第三大原因，其五年生存率低至10%，是一种预后极差的恶性肿瘤。胰腺导管腺癌（Pancreatic ductal adenocarcinoma, ...